|

Tumor Infiltrating Lymphocytes (TIL) Clinical Trials

13 actively recruiting trials across 2 locations

No change since May 2026

Also known as: TIL

Pipeline

Early 1: 4Phase 1: 1Phase 2: 3Phase 1/2: 5

Top Sponsors

  • Essen Biotech5
  • Shanghai Juncell Therapeutics4
  • Udai Kammula3
  • H. Lee Moffitt Cancer Center and Research Institute1

Indications

Other9 trials

A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Early 1
A Study of GC101 TIL in Advanced Solid Tumors (TR)
Early 1
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
Early 1
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
Phase 1/2
Study of GC101 TIL in Brain Glioma (Soochow2)
Early 1
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1/2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1/2

Pittsburgh, Pennsylvania3 trials

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

UPMC Hillman Cancer Center

Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

UPMC Hillman Cancer Center

Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

UPMC Hillman Cancer Center

Phase 2

Tampa, Florida1 trial

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Moffitt Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.